Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23480278 | 0.74 | CTDSP1 (0.50) | TP53MAPTGAA | |
| SCHEMBL17716534 | 0.73 | ERAP1 (0.37) | MAPTGAA | |
| SCHEMBL1985951 | 0.72 | POLB (0.53) | — | |
| SCHEMBL18882648 | 0.72 | POLB (0.42) | TP53MAPTGAASMN1; SMN2 | |
| SCHEMBL18041269 | 0.72 | POLB (0.42) | TP53MAPTGAASMN1; SMN2 | |
| SCHEMBL14365796 | 0.72 | MAPT (0.53) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL23471909 | 0.72 | KDM4E (0.53) | TP53MAPTGAASMN1; SMN2RXFP1 | |
| SCHEMBL14365816 | 0.70 | MAPT (0.49) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL16645386 | 0.69 | KDM4E (0.56) | TP53MAPTGAASMN1; SMN2 | |
| SCHEMBL23395072 | 0.68 | KDM4E (0.42) | TP53MAPTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188535-A1 | Bioorthogonal Turn-on Probes | THE GENERAL HOSPITAL CORPORATION | 2020-06-18 | — | — | US | disclosed |
| US-20160121002-A1 | Bioorthogonal Turn-on Probes | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160121002-A1 | Bioorthogonal Turn-on Probes | MPI, TIPRL, BAZ1A | TP53 603/4885MAPT 1276/4885GAA 3617/4885 |
| US-20200188535-A1 | Bioorthogonal Turn-on Probes | ZYX, MPI, BAZ1A | TP53 635/4885MAPT 870/4885GAA 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.